We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.
Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.8 million for the nine months ended September 30, for 2024 and 2023...
Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm.Tevogenโs success...
Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm.Tevogenโs success...
WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (โTevogenโ or โTevogen Bio Holdings Inc.โ) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf...
Tevogen Bio is a fully functional biotech, with investor-valued assets over $10 billion achieved with under $40 million in spending.Approximately 78% of Tevogen Bio's common stock is held by...
Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline.Tevogen Bio created a data set containing known proteins in the HPV genome to identify...
WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (โTevogenโ or โTevogen Bio Holdings Inc.โ) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf...
Current timeline for drug development is 10-12 years and costs approximately $1-3 billion. Tevogenโs approach has the potential to shorten timelines and substantially reduce costs. Tevogenโs AI...
Regained compliance without effecting a reverse stock splitTevogen Bio CEO reaffirms his commitment to preserve shareholder value WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio...
CD8 Technology Services, LLC (โCD8 Technologyโ) to provide turn-key facility for Tevogen BioReinforces Tevogen Bioโs commitment to preserving shareholder valueExpected to further enhance Tevogen...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.435 | -23.3870967742 | 1.86 | 1.86 | 1.26 | 5551859 | 1.41693063 | CS |
4 | -1.585 | -52.657807309 | 3.01 | 3.09 | 1.01 | 8403966 | 2.15643945 | CS |
12 | 0.916 | 179.960707269 | 0.509 | 3.09 | 0.2556 | 17258468 | 1.56902398 | CS |
26 | 0.631 | 79.4710327456 | 0.794 | 3.09 | 0.2556 | 8167722 | 1.55355091 | CS |
52 | -2.675 | -65.243902439 | 4.1 | 21.09 | 0.2556 | 5693093 | 1.57186765 | CS |
156 | -2.675 | -65.243902439 | 4.1 | 21.09 | 0.2556 | 5693093 | 1.57186765 | CS |
260 | -2.675 | -65.243902439 | 4.1 | 21.09 | 0.2556 | 5693093 | 1.57186765 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions